

Remarks

Prior to entry of this Amendment, claims 63-88 and 108-112 were pending in the application. By this amendment, claims 108, 109, and 112 are amended and new claims 113-115 are added. Support for the new claims can be found throughout the specification, for instance in Examples 11, 12, 14, and 15.

After entry of this Amendment, **claims 63-88 and 108-114 are pending**. Applicants reserve the right to pursue in a related application any subject matter deemed to have been removed from consideration by this amendment. No new matter is added by these amendments.

As noted in the Response filed December 26, 2007, Applicants added new claims drawn to transgenic non-human animals and cells from such animals. These claims have been amended herein to be directed to animals that express at least one activating PDGFRA variant protein comprising the amino acid sequence shown in SEQ ID NO: 4, 6, 8, 10, 12, 21, 23, or 25. Applicants understand that the Office will assign claims 108-115 to a different Group than the Group(s) elected previously, and withdraw them as directed to a non-elected Group.

Conclusion

The Examiner is invited to telephone the undersigned if any questions remain concerning the requirement for restriction, or the comments made herein. Otherwise, the present application is ready for substantive examination, and such action is requested.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630